Treatment-resistant classical epidermolysis bullosa acquisita responding to rituximab [19]

British Journal of Dermatology

Volumn 157, Issue 2, 2007, Pages 417-419

  Sadler, E ^a   Schafleitner, B ^a   Lanschuetzer, C ^a   Laimer, M ^a   Pohla Gubo, G ^a   Hametner, R ^a   Hintner, H ^a   Bauer, J W ^a  

^a PARACELSUS MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; COLCHICINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DACLIZUMAB; GOLD DERIVATIVE; IMMUNOGLOBULIN; INFLUENZA VACCINE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PNEUMOCOCCUS VACCINE; RITUXIMAB;

ABSENCE OF SIDE EFFECTS; AGED; ANTIBODY TITER; CASE REPORT; DISEASE ACTIVITY; DRUG MEGADOSE; DRUG TREATMENT FAILURE; EPIDERMOLYSIS BULLOSA ACQUISITA; FEMALE; HISTOLOGY; HUMAN; IMMUNOFLUORESCENCE; IMMUNOSUPPRESSIVE TREATMENT; INFLUENZA; LETTER; LOW DRUG DOSE; OUTCOME ASSESSMENT; PERCUTANEOUS ENDOSCOPIC GASTROSTOMY; PLASMAPHERESIS; PRIORITY JOURNAL; STREPTOCOCCUS INFECTION; TRACHEOTOMY; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT OBSTRUCTION;

AGED; ANTIBODIES, MONOCLONAL; DERMATOLOGIC AGENTS; EPIDERMOLYSIS BULLOSA ACQUISITA; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; TREATMENT FAILURE;

EID: 34447518987     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2007.08048.x     Document Type: Letter

References (10)

1. Hallel-Halevy D, Nadelman C, Chen M, Woodley DT. Epidermolysis bullosa acquisita: update and review. Clin Dermatol 2001 19 : 712 18.
2. Engineer L, Ahmed AR. Emerging treatment for epidermolysis bullosa acquisita. J Am Acad Dermatol 2001 44 : 818 28.
3. Mutasim DF. Management of autoimmune bullous diseases: pharmacology and therapeutics. J Am Acad Dermatol 2004 51 : 859 77.
4. Bauer JW, Schaeppi H, Metze D et al. Ocular involvement in IgA-epidermolysis bullosa acquisita. Br J Dermatol 1999 141 : 887 92.
5. Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 2003 22 : 7359 68.
6. Boye J, Elter T, Engert A. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann Oncol 2003 14 : 520 35.
7. Treon SP, Anderson KC. The use of rituximab in the treatment of malignant and nonmalignant plasma cell disorders. Semin Oncol 2000 27 : 79 85.
8. Goebeler M, Herzog S, Broecker EB, Zillikens D. Rapid response of treatment-resistant pemphigus foliaceus to the anti-CD20 antibody rituximab. Br J Dermatol 2003 149 : 899 901.
9. Arin MJ, Engert A, Krieg T, Hunzelmann N. Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus. Br J Dermatol 2005 153 : 620 5.
10. Schmidt E, Benoit S, Broecker EB et al. Successful adjuvant treatment of recalcitrant epidermolysis bullosa acquisita with anti-CD20 antibody rituximab. Arch Dermatol 2006 142 : 147 50.